Boehringer Ingelheim has stated that it has completed a $650 million settlement of the U.S. Pradaxa court case. All is well that ends well.
The U.S. litigation regarding Pradaxa has been settled for the hefty amount of $650 million. The fact was ceded by Boehringer Ingelheim. Pradaxa stands for dabigatran etexilate mesylate. The therapeutic effects of this drug have been demonstrated time after time.
Don't Miss: This is How to Find a Nintendo Switch in Stock
Boehringer Ingelheim has always supported the product and never for a single second doubted its validity and genuineness. It knew from the start that the plaintiff’s nitpicking had no meaning to it. The settlement has gotten a large hurdle out of the way.
"Time and again, the benefits and safety of PRADAXA have been confirmed," said Desiree Ralls-Morrison, senior vice president and general counsel, Boehringer Ingelheim USA Corporation. "BI stands resolutely behind PRADAXA and believed from the outset that the plaintiffs' claims lacked merit. Notwithstanding our strong belief that we would prevail in these lawsuits, this settlement allows BI to avoid the distraction and uncertainty of lengthy litigation and focus on our mission of improving patients' lives."
Boehringer Ingelheim has always held its workers in great esteem. They and the researchers tirelessly engaged in labor for years in order to make this drug. And today Pradaxa happens to be the first anticoagulant which can be taken orally. It has the full approval of the FDA and can remarkably cut the chances of stroke and embolism.
Since its inception, Boehringer Ingelheim has advised doctors and medical personnel regarding the proper and suitable usage of the drug. Pradaxa has been shown to be a better medicament than warfarin especially in the prevention of ischemic strokes.
After much dilly-dallying the FDA gave the go ahead signal for the drug’s manufacture and distribution. All the signs show that it is a safe and reliable medicine that cannot be matched by any other drug in the market.
"This settlement does not change the facts about PRADAXA or its importance to patients. From the time PRADAXA launched, BI properly advised doctors and patients about its benefits and safety, working closely with FDA, European Medicines Agency (EMA) and other regulators to ensure doctors and patients had the information they needed," said Desiree Ralls-Morrison.
There may be a few side effects which need to be taken into consideration but they are minimal. Flow of blood, allergic response and a few other special conditions and cases make the drug one which should be used with care.
Otherwise it is the safest and most stable pill to be had for your troubles. With the settlement of the case, Pradaxa has made it to the stage where it will be freely available in the United States.